Provectus Biopharmaceuticals Announces Stockholder Approval to Undertake Reverse Split of Outstanding Equities and Reduce Number of Authorized Equities by Same Ratio
26 juin 2023 07h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, June 26, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company’s shareholders have approved the proposals of Provectus’s Board of Directors (Board) to seek...
Global Drug Discovery Outsourcing Market to 2030: Players Include Merck & Co, Thermos Fisher Scientific, Dalton Pharma Services and Oncodesign
20 juin 2023 06h33 HE
|
Research and Markets
Dublin, June 20, 2023 (GLOBE NEWSWIRE) -- The "Drug Discovery Outsourcing Market Size, Share & Trends Analysis Report 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.The...
invIOs presents exciting preclinical data showing that immune-activating small molecule INV501 induces strong cytotoxic activity against solid tumors
19 juin 2023 08h30 HE
|
invIOs GmbH
INV501, a potentially first-in-class compound, induces strong anti-tumor immune responses in preclinical models in different solid tumor indicationsTreatment with INV501 significantly inhibits tumor...
Constrained Peptide Drugs Global Market 2023: Sector is Expected to Reach $17.28 Billion by 2030 at a CAGR of 38.94%
09 juin 2023 09h03 HE
|
Research and Markets
Dublin, June 09, 2023 (GLOBE NEWSWIRE) -- The "Constrained Peptide Drugs Market - A Global and Regional Analysis: Focus on Peptide Type, Product, and Region-Wise Analysis - Analysis and Forecast,...
ConSynance Therapeutics Reports Positive Phase 1 Results for CSTI-500 in Prader-Willi Syndrome Patients
30 mai 2023 10h00 HE
|
ConSynance Therapeutics
RENSSELAER, New York, May 30, 2023 (GLOBE NEWSWIRE) -- ConSynance Therapeutics, Inc., an emerging biopharmaceutical firm focused on developing novel therapies for rare central nervous system (CNS)...
Technology Advances in Senolytics 2023: Innovative Drug Development Culture Working to Prolong Health Spans and Eliminate Aging Cells
26 mai 2023 05h53 HE
|
Research and Markets
Dublin, May 26, 2023 (GLOBE NEWSWIRE) -- The "Technology Advances in Senolytics" report has been added to ResearchAndMarkets.com's offering. Senolytics is a relatively new field of development...
Atypical Teratoid Rhabdoid Tumors (ATRT) Pipeline Insights Report 2023 Featuring Novartis Pharmaceuticals, Ipsen Pharma, Chimerix, Exelixis, & Takeda Pharmaceuticals
23 mai 2023 08h58 HE
|
Research and Markets
Dublin, May 23, 2023 (GLOBE NEWSWIRE) -- The "Atypical Teratoid Rhabdoid Tumors (ATRT) - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.com's offering.This report...
Drafting Effective Pharmaceutical Patents Training Course
22 mai 2023 04h53 HE
|
Research and Markets
Dublin, May 22, 2023 (GLOBE NEWSWIRE) -- The "Drafting Effective Pharmaceutical Patents Training Course" conference has been added to ResearchAndMarkets.com's offering. The highly complex area of...
Global Active Pharmaceutical Ingredients Market Report 2023: Sector to Reach $386.2 Billion by 2032 with a 6.4% CAGR
05 mai 2023 04h48 HE
|
Research and Markets
Dublin, May 05, 2023 (GLOBE NEWSWIRE) -- The "Global Active Pharmaceutical Ingredients Market 2022-2032 by Molecule, Synthesis, Manufacturing Process, Therapeutic Application, Drug Type, and Region:...
Dalriada brings in former Evotec executive Adam Davenport to lead strategy execution as Chief R&D Officer
03 mai 2023 02h00 HE
|
Dalriada
TORONTO, May 03, 2023 (GLOBE NEWSWIRE) -- Dalriada, a leading Canadian contract research organization specializing in small molecule therapies, announces today that it has strengthened its executive...